

Pathricia V Tilstam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914267/publications.pdf>

Version: 2024-02-01

18
papers

548
citations

623734

14
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

951
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Non-activatable mutant of inhibitor of kappa B kinase $\hat{\pm}$ (IKK $\hat{\pm}$) exerts vascular site-specific effects on atherosclerosis in Apoe-deficient mice. <i>Atherosclerosis</i> , 2020, 292, 23-30. | 0.8 | 3 |
| 2 | Differential regulation of macrophage activation by the MIF cytokine superfamily members MIF and MIF $\hat{\pm}$ in adipose tissue during endotoxemia. <i>FASEB Journal</i> , 2020, 34, 4219-4233. | 0.5 | 24 |
| 3 | Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 733-744. | 3.4 | 82 |
| 4 | A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity. <i>Journal of Biological Chemistry</i> , 2019, 294, 18522-18531. | 3.4 | 20 |
| 5 | Elucidating the role of an immunomodulatory protein in cancer: From protein expression to functional characterization. <i>Methods in Enzymology</i> , 2019, 629, 307-360. | 1.0 | 11 |
| 6 | Macrophage migration inhibitory factor regulates innate $\hat{\beta}$ 1 $\hat{\tau}$ cell responses via IL $\hat{\pm}$ 17 expression. <i>FASEB Journal</i> , 2019, 33, 6919-6932. | 0.5 | 8 |
| 7 | Endothelial cell $\hat{\pm}$ secreted MIF reduces pericyte contractility and enhances neutrophil extravasation. <i>FASEB Journal</i> , 2019, 33, 2171-2186. | 0.5 | 24 |
| 8 | <i>Mif</i> deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis. <i>FASEB Journal</i> , 2018, 32, 4428-4443. | 0.5 | 24 |
| 9 | MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 671-683. | 3.4 | 62 |
| 10 | Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2766-E2775. | 7.1 | 40 |
| 11 | D $\hat{\pm}$ opachrome tautomerase in adipose tissue inflammation and wound repair. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 35-45. | 3.6 | 18 |
| 12 | Characterization of adipose tissue macrophages and adipose-derived stem cells in critical wounds. <i>PeerJ</i> , 2017, 5, e2824. | 2.0 | 10 |
| 13 | <i>MIF</i> allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7917-E7926. | 7.1 | 54 |
| 14 | PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 81, 23-33. | 1.9 | 29 |
| 15 | Deficiency of Endothelial <i>Cxcr4</i> Reduces Reendothelialization and Enhances Neointimal Hyperplasia After Vascular Injury in Atherosclerosis-Prone Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1209-1220. | 2.4 | 57 |
| 16 | Deficiency of the Sialyltransferase <i>St3Gal4</i> Reduces Ccl5-Mediated Myeloid Cell Recruitment and Arrest. <i>Circulation Research</i> , 2014, 114, 976-981. | 4.5 | 43 |
| 17 | Bone Marrow-Specific Knock-In of a Non-Activatable <i>Ikk$\hat{\pm}$</i> Kinase Mutant Influences Haematopoiesis but Not Atherosclerosis in Apoe-Deficient Mice. <i>PLoS ONE</i> , 2014, 9, e87452. | 2.5 | 14 |
| 18 | Endothelial CSN5 impairs NF $\hat{\pm}$ B activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. <i>Thrombosis and Haemostasis</i> , 2013, 110, 141-152. | 3.4 | 25 |